Eli Lilly CDR (CAD Hedged)
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- Conditions
- Ovarian CancerRecurrent Solid TumorUrinary Bladder NeoplasmEsophageal CancerRenal Pelvis CancerAdvanced Solid TumorProstate CancerMetastatic Solid TumorTriple Negative Breast CancerBladder Cancer
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 490
- Registration Number
- NCT06238479
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 12
- Registration Number
- NCT06235983
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
🇨🇳The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight and Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06230523
- Locations
- 🇺🇸
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona, United States
🇺🇸Headlands Research - Scottsdale, Scottsdale, Arizona, United States
🇺🇸The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson, Arizona, United States
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT06220669
- Locations
- 🇺🇸
Healthcare Innovations Institute, LLC, Coral Springs, Florida, United States
🇺🇸Royal Palm Medical Group, Fort Myers, Florida, United States
🇺🇸Eastern Medical Group Research, Fort Myers, Florida, United States
A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06215430
- Locations
- 🇺🇸
Covance Clinical Research Unit, Dallas, Texas, United States
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT06215521
- Locations
- 🇺🇸
Covance Clinical Research Unit 1341 Mockingbird Lane, Dallas, Texas, United States
🇺🇸Covance Clinical Research Unit 3402 Kinsman Blvd, Madison, Wisconsin, United States
A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT06194500
- Locations
- 🇬🇧
Fortrea Clinical Research Unit, Holbeck, Leeds, United Kingdom
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06194214
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT06190691
- Locations
- 🇺🇸
Orange County Research Institute, Anaheim, California, United States
🇺🇸Orange County Research Center, Tustin, California, United States
🇺🇸Riverside Clinical Research, Edgewater, Florida, United States
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06190678
- Locations
- 🇺🇸
Orange County Research Institute, Anaheim, California, United States
🇺🇸Riverside Clinical Research, Edgewater, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States